Pipeline

Growing a pipeline with potential global reach

Product

Indication

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Oncology

Product

Tebentafusp/IMCgp100

Indication

Uveal melanoma

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Product

GSK01 (NY-ESO-1)

Indication

NY-ESO-1 expressing malignancies

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Product

IMC-C103C (MAGE-A4)

Indication

MAGE-A4 expressing malignancies

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Product

IMC-F106C (PRAME)

Indication

Advanced solid tumours

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Product

IMC-J110C

Indication

Advanced solid tumours

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Infectious Diseases

Product

IMC-I109V

Indication

Hepatitis B Virus (HBV)

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Product

IMC-M113V

Indication

Human Immunodeficiency Virus (HIV)

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

Autoimmune Diseases

Product

Autoimmune program

Indication

Type 1 Diabetes

Stage

ImmTAC generation

IND enabling

Phase I/II

Pivotal

All trademarks, company and product names or logos are the property of their respective owners.

The efficacy and safety of the molecules under investigation have not yet been established. There is no guarantee that pipeline molecules will receive approval and become commercially available for the uses being investigated as drug development is uncertain and agents in development may be terminated along the development process. The above information is accurate as of April 2020.